These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27221794)

  • 21. Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug.
    Ohmori K; Hasegawa K; Tamura T; Miyake K; Matsubara M; Masaki S; Karasawa A; Urayama N; Horikoshi K; Kajita J; Hasegawa M; Taniguchi K; Komada T; Kawamoto Y
    Arzneimittelforschung; 2004; 54(12):809-29. PubMed ID: 15646365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells.
    Cook EB; Stahl JL; Barney NP; Graziano FM
    Ann Allergy Asthma Immunol; 2001 Nov; 87(5):424-9. PubMed ID: 11730187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis.
    Abelson MB; Gomes PJ; Pasquine T; Edwards MR; Gross RD; Robertson SM
    Allergy Asthma Proc; 2007; 28(4):427-33. PubMed ID: 17883910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital.
    Sruthi V; Reddy RN; Sowmini K; Grace NS
    Indian J Pharmacol; 2020; 52(6):476-481. PubMed ID: 33666188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.
    Vogelson CT; Abelson MB; Pasquine T; Stephens DM; Gamache DA; Gross RD; Robertson SM; Yanni JM
    Allergy Asthma Proc; 2004; 25(1):69-75. PubMed ID: 15055565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis.
    Scoper SV; Berdy GJ; Lichtenstein SJ; Rubin JM; Bloomenstein M; Prouty RE; Vogelson CT; Edwards MR; Waycaster C; Pasquine T; Gross RD; Robertson SM
    Adv Ther; 2007; 24(6):1221-32. PubMed ID: 18165204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model.
    Abelson MB
    Ann Allergy Asthma Immunol; 1998 Sep; 81(3):211-8. PubMed ID: 9759796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle-controlled study.
    Liu RF; Wu XX; Wang X; Gao J; Zhou J; Zhao Q
    Int Forum Allergy Rhinol; 2017 Apr; 7(4):393-398. PubMed ID: 27869354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
    Abelson MB; Spangler DL; Epstein AB; Mah FS; Crampton HJ
    Curr Eye Res; 2007 Dec; 32(12):1017-22. PubMed ID: 18085465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model.
    McLaurin E; Narvekar A; Gomes P; Adewale A; Torkildsen G
    Cornea; 2015 Oct; 34(10):1245-51. PubMed ID: 26266427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential regulation of IL-4 expression and degranulation by anti-allergic olopatadine in rat basophilic leukemia (RBL-2H3) cells.
    Matsubara M; Masaki S; Ohmori K; Karasawa A; Hasegawa K
    Biochem Pharmacol; 2004 Apr; 67(7):1315-26. PubMed ID: 15013847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.
    Gong L; Sun X; Qu J; Wang L; Zhang M; Zhang H; Wang L; Gu Y; Elion-Mboussa A; Roy L; Zhu B
    Clin Ther; 2012 Jun; 34(6):1259-1272.e1. PubMed ID: 22627057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
    Kida T; Fujii A; Sakai O; Iemura M; Atsumi I; Wada T; Sakaki H
    Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density.
    Corum I; Yeniad B; Bilgin LK; Ilhan R
    J Ocul Pharmacol Ther; 2005 Oct; 21(5):400-5. PubMed ID: 16245967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
    Fujishima H; Ohashi Y; Takamura E
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Moxifloxacin-imprinted silicone-based hydrogels as contact lens materials for extended drug release.
    Silva D; de Sousa HC; Gil MH; Santos LF; Oom MS; Alvarez-Lorenzo C; Saramago B; Serro AP
    Eur J Pharm Sci; 2021 Jan; 156():105591. PubMed ID: 33065225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models.
    Tamura T
    Asia Pac Allergy; 2012 Apr; 2(2):115-21. PubMed ID: 22701861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Azelastine is more potent than olopatadine n inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells.
    Kempuraj D; Huang M; Kandere K; Boucher W; Letourneau R; Jeudy S; Fitzgerald K; Spear K; Athanasiou A; Theoharides TC
    Ann Allergy Asthma Immunol; 2002 May; 88(5):501-6. PubMed ID: 12027072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis.
    Rosenwasser LJ; Mahr T; Abelson MB; Gomes PJ; Kennedy K
    Allergy Asthma Proc; 2008; 29(6):644-53. PubMed ID: 19063816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel anti-biofouling and drug releasing materials for contact lenses.
    Ogawa H; Nakaji-Hirabayashi T; Matsumura K; Yoshikawa C; Kitano H; Saruwatari Y
    Colloids Surf B Biointerfaces; 2020 May; 189():110859. PubMed ID: 32086022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.